Prescription medication · Rapid-Acting Insulin

insulin glulisine

Also sold as Apidra. Apidra is used to improve blood sugar control in adults and children with diabetes.

Data updated 2026-05-15

9,944
FDA reportsLightly reported
9
InteractionsFew interactions
$8.17
Brand price (NADAC)

What the data shows

insulin glulisine (Apidra) is a prescription Rapid-Acting Insulin, reported less often than most tracked drugs (9,944 FDA reports), with 9 documented drug interactions.

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

insulin glulisine (Apidra) is a prescription Rapid-Acting Insulin. Apidra is used to improve blood sugar control in adults and children with diabetes.

Apidra is a rapid-acting insulin that helps control blood sugar levels in people with diabetes. It works quickly to lower blood sugar after meals.

Drug Pricing (NADAC)

Brand Price

$8.17/unit

Generic Available

No

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

View Alternatives → Compare with Another Drug → Full Side Effects Report →

What it does

Apidra is used to improve blood sugar control in adults and children with diabetes.

Common side effects

Upper respiratory infection, Nasopharyngitis (common cold), Hypoglycemia (low blood sugar)

Key warnings

Never share your Apidra SoloStar pen with anyone else, even if you change the needle.

The sections below are summarized in plain English from insulin glulisine's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Apidra is a type of insulin that works fast. It helps your body use sugar from the food you eat. This lowers the amount of sugar in your blood.

Side Effects (from patient reports)

Based on 9,944 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for insulin glulisine, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS) As of 2025

Reports over time

Adverse-event reports filed for insulin glulisine each year to the FDA Adverse Event Reporting System (FAERS).

05001,0001,500 20052008201120142017202020232025 289

Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.

Where insulin glulisine sits

insulin glulisine has more FDA adverse-event reports than 39% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.

fewest reports most reports

Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is insulin glulisine; the line is the median (50th percentile).

FDA Adverse Event Report Analysis

Detailed analysis of 9,944 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2005–2025.

Total Reports

9,944

Reports Mentioning Death

795

8.0% of reports — not proof of cause

Hospitalization Reports

4,001

Top Indication

Diabetes Mellitus

Gender Distribution

Female 4,904 (53%)
Male 4,360 (47%)

Age Distribution

0–17 211
18–44 970
45–64 2,851
65–74 1,861
75+ 1,372

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 BLOOD GLUCOSE INCREASED 1,526
2 HYPOGLYCAEMIA 756
3 HYPERGLYCAEMIA 634
5 BLOOD GLUCOSE DECREASED 445
6 DIZZINESS 401
7 MALAISE 392
8 DYSPNOEA 383
9 NAUSEA 370
10 VOMITING 335
11 ACUTE KIDNEY INJURY 304
12 FATIGUE 297
13 ASTHENIA 293
14 DIARRHOEA 279
15 PAIN 271
16 FALL 269

Reactions in Death Reports

DEATH 207
RENAL FAILURE 78
GASTROINTESTINAL HAEMORRHAGE 56
PNEUMONIA 49
BALANCE DISORDER 48
BLOOD GLUCOSE FLUCTUATION 48
COGNITIVE DISORDER 48
CONTRAINDICATED PRODUCT ADMINISTERED 47
HAEMATOMA 47
URINARY INCONTINENCE 47

Reactions in Hospitalization Reports

BLOOD GLUCOSE INCREASED 359
HYPOGLYCAEMIA 335
HYPERGLYCAEMIA 330
DYSPNOEA 246
ACUTE KIDNEY INJURY 225
VOMITING 218
DIABETIC KETOACIDOSIS 192
PNEUMONIA 170
MALAISE 162
ASTHENIA 160

Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Never share your Apidra SoloStar pen with anyone else, even if you change the needle. Sharing pens can spread blood-borne diseases. Changes in your insulin regimen should be made carefully under medical supervision because it can cause hyperglycemia or hypoglycemia. Low potassium levels in your blood can occur and may be life-threatening. Watch for signs of heart failure if you are also taking thiazolidinediones (TZDs).

Known Drug Interactions

moderate fluoxetine

7 DRUG INTERACTIONS Table 6: Clinically Significant Drug Interactions with APIDRA Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.

Mechanism: Fluoxetine can increase the risk of low blood sugar when taken with insulin.

moderate pramlintide

7 DRUG INTERACTIONS Table 6: Clinically Significant Drug Interactions with APIDRA Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.

Mechanism: Pramlintide can increase the risk of low blood sugar when taken with insulin.

moderate octreotide

7 DRUG INTERACTIONS Table 6: Clinically Significant Drug Interactions with APIDRA Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.

Mechanism: Octreotide can increase the risk of low blood sugar when taken with insulin.

Drugs that May Decrease the Blood Glucose Lowering Effect of APIDRA Drugs: Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, phenothiazine derivatives, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.

Mechanism: Albuterol can cause blood sugar levels to rise, which counteracts the effect of the insulin.

Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of APIDRA Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. Drugs that May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine. ( 7 ) Antiadrenergic Drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine): Signs and symptoms of hypoglycemia may be reduced or absent.

Mechanism: Clonidine can change how insulin affects your blood sugar and can also hide the warning signs of low blood sugar.

Check all your medications →

This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.

Common Questions

What should I do if my blood sugar is too high?
Follow your doctor's instructions for managing high blood sugar. This may include adjusting your insulin dose or diet.
Can I mix Apidra with other insulins?
Do not mix Apidra with other insulins except for NPH insulin. If mixing with NPH, draw Apidra into the syringe first and inject immediately.
How often should I check my blood sugar?
Check your blood sugar as often as your doctor recommends. This may be more frequent when you start Apidra or if your insulin regimen changes.
What are the symptoms of low blood sugar?
Symptoms of low blood sugar can include sweating, shaking, dizziness, hunger, confusion, and rapid heartbeat.
What should I do if I have low blood sugar?
If you have low blood sugar, eat or drink something with sugar in it, such as glucose tablets, juice, or regular soda.
Can other medicines affect Apidra?
Yes, many medicines can affect your blood sugar levels and may require your Apidra dose to be adjusted. Tell your doctor about all the medicines you take.
What if my insulin pump malfunctions?
If your insulin pump malfunctions, monitor your blood sugar and administer Apidra by subcutaneous injection.
How long does Apidra last in my system?
Apidra is a rapid-acting insulin, so its effects last for a shorter period compared to longer-acting insulins.
Can I travel with Apidra?
Yes, you can travel with Apidra. Keep it in its original packaging and avoid exposing it to extreme temperatures.
What do I do with used needles?
Dispose of used needles in a sharps container to prevent accidental injury.
What are the common side effects of insulin glulisine?
The registry lists Upper respiratory infection, Nasopharyngitis (common cold), Hypoglycemia (low blood sugar), Edema peripheral (swelling in hands or feet), Arthralgia (joint pain) among the most-reported FAERS reaction terms for insulin glulisine. The compiled record contains 9,944 FDA adverse-event reports. These counts are not an individual symptom assessment.
Does insulin glulisine interact with other medications?
The registry has 9 documented interaction rows for insulin glulisine. Notable source-record pairings include fluoxetine, pramlintide, octreotide. These rows are not a complete medication review.
What drug class is insulin glulisine?
insulin glulisine belongs to the Rapid-Acting Insulin drug class. It requires a prescription (Rx). Apidra is used to improve blood sugar control in adults and children with diabetes.
What pregnancy or breastfeeding source fields are listed for insulin glulisine?
The FDA label for insulin glulisine contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Other drugs grouped near insulin glulisine - same-class peers and common alternatives.

Compare insulin glulisine vs acarbose side-by-side →

Compare beyond drug class

Nationwide peers by FAERS volume & death-report share

Two PlainMeds-derived comparison paths for insulin glulisine: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.

Medication Guides

Save on insulin glulisine

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for insulin glulisine

The FDA label for insulin glulisine (sold under brand names such as Apidra) classifies it as a prescription-only medication in the Rapid-Acting Insulin class. Apidra is used to improve blood sugar control in adults and children with diabetes. Official labeling lists 6 commonly reported side effects, including Upper respiratory infection, Nasopharyngitis (common cold), Hypoglycemia (low blood sugar).

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 9,944 voluntary reports. The database also lists 9 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: November 25, 2025

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page